Intercept Pharmaceuticals (ICPT) Bullish Stance Reiterated at Needham & Company
Tweet Send to a Friend
Needham & Company analyst Alan Carr reiterated a Buy rating and $500 price target on Intercept Pharmaceuticals (NASDAQ: ICPT) following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
